Characteristics and outcomes of autoimmune hemolytic anemia after pediatric allogeneic stem cell transplant.
Kirsty HillierEmily M HarrisLaura BerbertSung-Yun PaiRachael F GracePublished in: Pediatric blood & cancer (2021)
AIHA after HSCT is rare but occurs more commonly in patients transplanted for nonmalignant diagnoses. While some pediatric patients who develop AIHA after transplant can be managed on current immunosuppression and supportive care, many require AIHA-directed therapy including second-line medications.
Keyphrases
- stem cells
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- healthcare
- stem cell transplantation
- palliative care
- bone marrow
- multiple sclerosis
- peritoneal dialysis
- hematopoietic stem cell
- low dose
- metabolic syndrome
- pain management
- mesenchymal stem cells
- high dose
- chronic pain
- skeletal muscle
- patient reported